Tag - TELO

Developments

Telomir’s lead candidate prevents cellular aging in patient-derived cells from children with Progeria

Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing that Telomir-1 prevented cellular aging in patient-derived cells from children with progeria—Hutchinson-Gilford Progeria Syndrome (HGPS)—an...

June 18, 2025

Executive Moves

Telo appoints John Farlinger to BOD

Telo Genomics (TSXV:TELO) announced the appointment of John Farlinger to its board of directors (BOD) and will serve as chair of the company’s audit committee. With more than 30 years of experience in telecom...

April 4, 2025

Tag - TELO

Telomir’s lead candidate prevents cellular aging in patient-derived cells from children with Progeria

Telo appoints John Farlinger to BOD

Subscribe